Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
The value of the veterinary professionalVeterinary record, 2019-03, Vol.184 (13), p.415-415 [Peer Reviewed Journal]British Veterinary Association ;British Veterinary Association 2019 ;British Veterinary Association2019 ;ISSN: 0042-4900 ;EISSN: 2042-7670 ;DOI: 10.1136/vr.l1384 ;PMID: 30926705Full text available |
|
2 |
Material Type: Article
|
POS0599 DISEASE ACTIVITY IN PATIENTS WITH RA BY SEROSTATUS AND TREATMENT LINE, FOLLOWING TREATMENT WITH ABATACEPT: RESULTS FROM AN INTERNATIONAL OBSERVATIONAL STUDYAnnals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.533-534 [Peer Reviewed Journal]2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-eular.928Full text available |
|
3 |
Material Type: Article
|
AB0478 FRENCH REAL-LIFE DATA ON THE 18-MONTH EFFECTIVENESS OF TOFACITINIB ACCORDING TO CONCOMITANT USE OF CSDMARD IN PATIENTS WITH RHEUMATOID ARTHRITIS: INTERIM RESULTS OF THE OBSERVATIONAL STUDY, DEFACTOAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1432-1432 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.4187Full text available |
|
4 |
Material Type: Article
|
OP0051 LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT IN THE PHASE 3 PLACEBO-CONTROLLED TULIP LONG-TERM EXTENSION TRIAL OF ANIFROLUMABAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.33-34 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.1568Full text available |
|
5 |
Material Type: Article
|
POS0715 SUSTAINED REMISSION FROM WEEKS 16 TO 52 AND WEEKS 24 TO 52 IN PATIENTS TREATED WITH SARILUMAB: POST-HOC ANALYSIS OF SAPHYR TRIAL IN PATIENTS WITH POLYMYALGIA RHEUMATICAAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.644-645 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.1989Full text available |
|
6 |
Material Type: Article
|
AB0539 IXEKIZUMAB TREATMENT RESPONSE: CONSISTENCY OVER TIME AND AT EACH VISIT IN PSORIATIC ARTHRITISAnnals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.1301-1302 [Peer Reviewed Journal]2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-eular.1514Full text available |
|
7 |
Material Type: Article
|
AB0207 ANALYSIS OF ABATACEPT TREATMENT RETENTION AND EFFICACY ACCORDING TO DISEASE DURATION AND TREATMENT LINE IN A REAL-WORLD SETTINGAnnals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.1128-1130 [Peer Reviewed Journal]2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-eular.955Full text available |
|
8 |
Material Type: Article
|
SAT0180 Two-year consolidated safety data for abp 501 in patients with moderate to severe rheumatoid arthritisAnnals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.951 [Peer Reviewed Journal]2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.6746Full text available |
|
9 |
Material Type: Article
|
SAT0253 Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective studyAnnals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.988 [Peer Reviewed Journal]2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.2000Full text available |
|
10 |
Material Type: Article
|
POS0278 EFFICACY AND SAFETY OF SECUKINUMAB IN JUVENILE IDIOPATHIC ARTHRITIS: INTERIM RESULTS FROM THE EXTENSION OF THE JUNIPERA TRIALAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.379-380 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.3679Full text available |
|
11 |
Material Type: Article
|
POS1365 STRUCTURAL SEVERITY IN KNEE OSTEOARTHRITIS IMPACTS TREATMENT RESPONSE: A POST HOC POOLED ANALYSIS OF LORECIVIVINT CLINICAL TRIALSAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1035-1035 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.2791Full text available |
|
12 |
Material Type: Article
|
POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMMEAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.884-885 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.82Full text available |
|
13 |
Material Type: Article
|
POS1349 A BIOMARKER APPROACH TO DATA-DRIVEN IDENTIFICATION OF ENDOTYPES IN KNEE OA PATIENTSAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1026-1026 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.3433Full text available |
|
14 |
Material Type: Article
|
POS1543 EFFICACY OF RISANKIZUMAB IN THE TREATMENT OF PsA PATIENTS WITH LIMITED AND EXTENSIVE JOINT INVOLVEMENTAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1139-1140 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.3273Full text available |
|
15 |
Material Type: Article
|
POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMALAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1133-1134 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.1694Full text available |
|
16 |
Material Type: Article
|
POS1501 LUPUSNET – A FEDERATED MODEL/NETWORK TO SUPPORT REAL-WORLD DATA RESEARCH IN SYSTEMIC LUPUS ERYTHEMATOSUSAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1108-1108 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.3017Full text available |
|
17 |
Material Type: Article
|
OP0074 RADIOGRAPHIC AND PAIN OUTCOMES FROM A PHASE 3 EXTENSION STUDY EVALUATING THE SAFETY AND EFFICACY OF LORECIVIVINT IN SUBJECTS WITH SEVERE OSTEOARTHRITIS OF THE KNEE (OA-07): SINGLE BLIND AND CROSSOVER RESULTSAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.50-51 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.2833Full text available |
|
18 |
Material Type: Article
|
POS0751 PHARMACOKINETICS OF UPADACITINIB IN PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITISAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.666-667 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.3883Full text available |
|
19 |
Material Type: Article
|
POS0834 LONG-TERM EXTENSION STUDY OF THE SAFETY AND EFFICACY OF NEUROIMMUNE MODULATION USING A VAGUS NERVE STIMULATION DEVICE IN PATIENTS WITH RHEUMATOID ARTHRITISAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.714-714 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.5037Full text available |
|
20 |
Material Type: Article
|
OP0139 EFFICACY AND SAFETY OF ABBV-599 HIGH DOSE (ELSUBRUTINIB 60 MG AND UPADACITINIB 30 MG) AND UPADACITINIB MONOTHERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.91-92 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.2402Full text available |